CDCA7 promotes lung adenocarcinoma proliferation via regulating the cell cycle.
CDCA7 is overexpressed in several malignant cancers and is predicted by bioinformatics to be a candidate oncogene in lung adenocarcinoma (LUAD). However, the clinical and biological function of CDCA7 in LUAD has never been investigated. In this study, we used quantitative real-time RT-PCR and immunohistochemistry to determine the expression level and clinical significance of CDCA7. As a result, CDCA7 was significantly overexpressed in LUAD compared to adjacent normal tissues. Furthermore, overexpression of CDCA7 was positively associated with more advanced clinical features. Silencing CDCA7 inhibited cell proliferation in LUAD through G1 phase arrest and induction of apoptosis. In conclusion, CDCA7 can be used as a potential therapeutic target for new biomarkers and LUAD.